Medigus Receives First Purchase Order From The Johns Hopkins Hospital for Its MUSETM System
OMER, Israel, July 27, 2016 — Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Johns Hopkins Hospital, an integrated global health enterprise and one of the leading health care systems in the United States, has provided an initial purchase order (PO) for the MUSE™ system. The PO covers the cost of a MUSE system console and endoscopic device, which will be available for use on eligible patients suffering from GERD.
The Medigus Ultrasonic Surgical Endostapler, or MUSE system, is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device is equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).
“We thank Johns Hopkins for its recognition of our technology as a minimally-invasive modality that addresses the widening gap in GERD treatment between drug therapy and invasive surgery,” said Chris Rowland, CEO of Medigus. “GERD is a pervasive disorder that has the potential to worsen into more severe conditions if not properly addressed at the early stages. We are proud to have this interventional endoscopic treatment be available to Baltimore area patients.”
According to experts, 60 percent of the American adult population will experience some type of GERD within year and 20 to 30 percent will have weekly symptoms. GERD, the medical term for acid reflux, occurs when the base of the lower esophageal sphincter doesn’t properly close after swallowing, which allows acids to back up (or reflux) into the esophagus, causing discomfort. Though patients may experience symptom relief through acid-reducing medications called Proton Pump Inhibitors (PPIs), these do not treat the anatomical source of GERD, leaving opportunity for the disease to progress to a more severe condition, including esophageal cancer.
To learn how MUSE works or to find a physician near you who offers this treatment, please visit www.refluxhelp.com.